Robert Temple, director of the Office of Medical Policy at the FDA's Center for Drug Evaluation and Research, has been quoted as saying that the declaration has unfortunately "moved from a purely ethical document to a document that is increasingly interested in social justice.
What does OMP stand for?
OMP stands for Office of Medical Policy (US FDA)
This definition appears very rarely and is found in the following Acronym Finder categories:
- Military and Government
See other definitions of OMP
We have 125 other meanings of OMP in our Acronym Attic
- O'Hare Airport Modernization Program
- Obras Misionales Pontificias (Spanish)
- Observatoire Midi-Pyrenees
- Occult Malignant Primary
- Occupational Maternity Pay (UK)
- Ocean Measurements Program
- Odor Management Plan (Department of Agriculture)
- Office Managing Partner
- Office of Major Projects (US DOC)
- Office of Marine Programs (University of Rhode Island)
Samples in periodicals archive:
FDA Office of Medical Policy Director Bob Temple suggested that progress is being made but sees hesitancy from both industry and regulators.
Temple, director of the FDA's office of medical policy.
The FDA also plans to make other changes, including establishing an Office of Counterterrorism and Emergency Operations, which will report to the Office of the Center Director; and realigning the Division of Scientific Investigations from the Office of Medical Policy into the Office of Compliance.
Speakers at the conference include top officials from the regulatory agencies, academia and industry: * Andrew von Eschenbach, MD, Acting Commissioner, FDA * Janet Woodcock, MD, Deputy Commissioner for Operations, FDA * Steven Galson, MD, Director, Center for Drug Evaluation and Research, FDA * Paul Seligman, MD, MPH, Associate Director for Safety Policy and Communications, FDA * Robert Temple, MD, Director, Office of Medical Policy, FDA * Steven E.
However, FDA Office of Medical Policy Director Robert Temple says data from an ongoing agency study of off-label use suggest current methods such as adverse event reports cast an adequate net to catch potentially dangerous off-label use.
Robert Temple, director of the Office of Medical Policy at FDA's Center for Drug Evaluation and Research.
We owe the world some guidance on this," Center for Drug Evaluation & Research Office of Medical Policy Director Robert Temple said Oct.